FRONTEO Co., Ltd. FRONTEO signs a contract with Daiichi Sankyo for optimization and analysis of toxicity information using Drug Discovery AI Factory

[FRONTEO Co., Ltd.] FRONTEO signs agreement with Daiichi Sankyo for optimization and analysis of toxicity information using Drug Discovery AI Factory ​
FRONTEO Co., Ltd. Press release: November 12, 2024 FRONTEO signs agreement with Daiichi Sankyo for optimization and analysis of toxicity information using Drug Discovery AI Factory Supporting the construction of an innovative exploration AI system that derives new knowledge from toxicity test databases and toxicity test reports FRONTEO Co., Ltd. (Head office: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter FRONTEO) is a subsidiary of Daiichi Sankyo Co., Ltd. (Head office: Chuo-ku, Tokyo, President and COO: Hiroyuki Okusawa, hereinafter Daiichi Sankyo Co., Ltd. We are pleased to announce that we have signed an agreement with Sankyo for the analysis of toxicity test database and text information of toxicity test reports using Drug Discovery AI Factory (DDAIF)*. Under this agreement, FRONTEO will introduce a system that allows for easy confirmation of toxicity interpretation on Daiichi Sankyo’s current toxicity test database, and an exploration AI system that supports the discovery of new knowledge and ideas through analysis of toxicity test reports. We will support the construction of *FRONTEO’s drug discovery experts, who are well-versed in AI and drug discovery, utilize the natural language processing technology and unique analysis methods of the specialized AI “KIBIT” developed in-house to search for target molecules and indications and AI drug discovery support service that provides supporting hypotheses
https://prcdn.freetls.fastly.net/release_image/6776/597/6776-597-6aa38f58decdf1b37737ddedee8decc0-3374×630.png

This system uses KIBIT to analyze the text information of the huge amount of toxicity test reports that Daiichi Sankyo owns or will accumulate in the future, as well as article information published on PubMed, and uses it to analyze the text information of the vast amount of toxicity test reports that Daiichi Sankyo owns or will accumulate in the future. We present the relationships between academic papers and toxicity test reports in the form of maps (diagrams) and lists that can be comprehensively and visually understood. Based on this information, by confirming relationships and trends in toxicity information that were previously unsuspected, it becomes possible to generate hypotheses for new mechanisms of toxicity, enabling drug discovery and development without being bound by preconceived notions. is expected.
https://prcdn.freetls.fastly.net/release_image/6776/597/6776-597-e75b012c1cc40c53a7ee744f9cdde1f1-730×296.png Figure: KIBIT converts papers and reports into hundreds of dimensional vectors (numeric values), compresses them into two dimensions, and plots them on a vector plane. Because conceptually similar papers and reports are distributed nearby, relationships between information can be seen from a bird’s-eye view, and similarities and relationships between toxicity test reports and papers that cannot be noticed with conventional approaches can be observed. can be discovered In recent years, research has progressed on techniques and methodologies that allow researchers to efficiently access the information they seek from vast amounts of bibliographic information. However, new discoveries from known bibliographic information still depend on researchers’ own creativity and methodologies. The reality is that it depends on chance. FRONTEO utilizes KIBIT to deploy DDAIF, which enables scientific and systematic discovery of unknown relationships that are not described from known literature information, contributing to innovative research and development of pharmaceutical companies. . ■About FRONTEO URL: https://www.fronteo.com/ FRONTEO supports the judgment of experts in various fields who face social issues day and night, creating a starting point for innovation by providing specialized AI “KIBIT” developed in-house. Our unique natural language processing technology (patented in Japan and the US), unlike general-purpose AI, enables high-speed and highly accurate analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps the analyzed information (visualizes the structure), KIBIT can directly influence the insights of experts. It is also used for generation and target search. Through KIBIT’s unique technology and approach, we aim to realize the philosophy of “providing solutions that do not overlook risks and opportunities buried in records, and realizing fairness in the information society.” We are promoting social implementation in various fields of legal tech AI. Founded in August 2003, listed on TSE Mothers (currently TSE Growth) on June 26, 2007. The company operates in Japan, the United States, South Korea, and Taiwan. Obtained a first-class medical device manufacturing and sales business license and registered a controlled medical device sales business. Capital: 898,618,000 yen (as of August 31, 2024). *FRONTEO, KIBIT, and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.